161 related articles for article (PubMed ID: 27048780)
1. Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men.
Sun WG; Liang CZ; Zheng QC; Hu XW; Li ZZ; Wu P
Asian J Androl; 2017; 19(4):463-467. PubMed ID: 27048780
[TBL] [Abstract][Full Text] [Related]
2. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
5. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.
Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G
BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
9. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
[TBL] [Abstract][Full Text] [Related]
10. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
11. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
[TBL] [Abstract][Full Text] [Related]
12. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].
Sun KX; Yan CL; Li ZY; Liu P; Zhang W; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):234-239. PubMed ID: 32306004
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.
Abrate A; Lazzeri M; Lughezzani G; Buffi N; Bini V; Haese A; de la Taille A; McNicholas T; Redorta JP; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Freschi M; Guazzoni G
BJU Int; 2015 Apr; 115(4):537-45. PubMed ID: 25130593
[TBL] [Abstract][Full Text] [Related]
16. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
Stephan C; Kahrs AM; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
Prostate; 2009 Feb; 69(2):198-207. PubMed ID: 18942119
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.
Huang YQ; Sun T; Zhong WD; Wu CL
Am J Clin Exp Urol; 2014; 2(4):343-50. PubMed ID: 25606581
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.
Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH
J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138
[TBL] [Abstract][Full Text] [Related]
20. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.
Yu GP; Na R; Ye DW; Qi J; Liu F; Chen HT; Wu YS; Zhang GM; Sun JL; Zhu Y; Huang LQ; Ren SC; Jiang DK; Zheng SL; Jiang HW; Sun YH; Ding Q; Xu J
Asian J Androl; 2016; 18(4):633-8. PubMed ID: 26975483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]